

| | |
|---------------------------|--|
| Name: | Fulvestrant-D3 |
| Lot#: | GR-16-165 |
| Test Date: | 10/28/2021 (re-test date:10/28/2026) |
| CAS No.: | 129453-61-8 (unlabelled) |
| MF: | C ₃₂ H ₄₄ D ₃ F ₅ O ₃ S |
| MW: | 609.79 |
| Appearance: | White Solid |
| Purity: | 97.6% by HPLC (average of two sample preparations); >98% atom D |
| ¹H-NMR: | Conforms (contains some MTBE) |
| MS-ESI (-) | Conforms (shows peaks at m/z = 608.36 [M-H] ⁻ and 654.37 [M+HCOOH-H] ⁻) |

Approved by:

Date: 10/29/2021




Viorica Rusu, QC/QA Manager

GR-16-165

Fulvestrant-D3
1H-NMR, 600 MHz
Solvent: DMSO-D6
Lot No.: GR-16-165




pp_2021_045_GR_16_165_1 76 (1.455) Sm (SG, 2x5.00); Sb (2,10.00); Cm (76:80-16:20x2.000)



ESI-MS spectrum for sample GR-16-165. Shows monoisotopic [M-H]- mass.


pp_2021_045_GR_16_165_1 76 (1.455) Sm (SG, 2x5.00); Sb (2,10.00); Cm (76:80-16:20x2.000)



Expansion of above showing intensity labels.

```

=====
Acq. Operator   : vrusu
Acq. Instrument : Instrument 1                Location : Vial 54
Injection Date  : 10/28/2021 1:31:10 PM
                                           Inj Volume : 10.0 µl
Acq. Method     : C:\CHEM32\1\METHODS\VR102821_165.M
Last changed    : 10/28/2021 1:30:15 PM by vrusu
Analysis Method : C:\CHEM32\1\METHODS\VR102921_165PM.M
Last changed    : 10/29/2021 11:48:30 AM by vrusu
  
```



=====
 Area Percent Report
 =====

```

Sorted By       : Signal
Calib. Data Modified : 10/29/2021 11:46:29 AM
Multiplier:     : 1.0000
Dilution:       : 1.0000
Use Multiplier & Dilution Factor with ISTDs
  
```

Signal 1: DAD1 A, Sig=220,4 Ref=360,5

| Peak # | RetTime [min] | Type | Width [min] | Area [mAU*s] | Area % | Name |
|--------|---------------|------|-------------|--------------|---------|----------------|
| 1 | 1.662 | BB | 0.0613 | 2.76566 | 0.0452 | ? |
| 2 | 1.924 | BB | 0.1399 | 3.04473 | 0.0498 | ? |
| 3 | 2.352 | BB | 0.0823 | 3.29590 | 0.0539 | ? |
| 4 | 2.612 | BB | 0.1089 | 9.44767 | 0.1545 | ? |
| 5 | 3.729 | VV | 0.0900 | 1.33244 | 0.0218 | ? |
| 6 | 3.967 | VB | 0.1337 | 5968.23047 | 97.6234 | Fulvestrant-D3 |
| 7 | 5.385 | BV | 0.1063 | 83.25667 | 1.3618 | ? |
| 8 | 5.629 | VV | 0.1158 | 32.08620 | 0.5248 | ? |

Sample Name: GR-16-165


| Peak # | RetTime [min] | Type | Width [min] | Area [mAU*s] | Area % | Name |
|--------|---------------|------|-------------|--------------|--------|------|
| 9 | 5.794 | VB | 0.1191 | 10.06340 | 0.1646 | ? |

Totals : 6113.52314

=====
*** End of Report ***

```

=====
Acq. Operator   : vrusu
Acq. Instrument : Instrument 1                Location : Vial 55
Injection Date  : 10/28/2021 1:48:06 PM
                                           Inj Volume : 10.0 µl
Acq. Method    : C:\CHEM32\1\METHODS\VR102821_165.M
Last changed   : 10/28/2021 1:47:14 PM by vrusu
Analysis Method: C:\CHEM32\1\METHODS\VR102921_165PM.M
Last changed   : 10/29/2021 11:48:30 AM by vrusu
  
```



Area Percent Report

```

Sorted By      : Signal
Calib. Data Modified : 10/29/2021 11:46:29 AM
Multiplier:    : 1.0000
Dilution:      : 1.0000
Use Multiplier & Dilution Factor with ISTDs
  
```

Signal 1: DAD1 A, Sig=220,4 Ref=360,5

| Peak # | RetTime [min] | Type | Width [min] | Area [mAU*s] | Area % | Name |
|--------|---------------|------|-------------|--------------|---------|----------------|
| 1 | 1.663 | BB | 0.0608 | 3.42120 | 0.0515 | ? |
| 2 | 2.352 | BB | 0.0837 | 4.15287 | 0.0625 | ? |
| 3 | 2.614 | BB | 0.1334 | 14.91203 | 0.2246 | ? |
| 4 | 3.250 | BB | 0.1611 | 3.97569 | 0.0599 | ? |
| 5 | 3.734 | BV | 0.1299 | 5.96095 | 0.0898 | ? |
| 6 | 3.968 | VB | 0.1320 | 6472.53467 | 97.4785 | Fulvestrant-D3 |
| 7 | 5.385 | BV | 0.1076 | 91.10538 | 1.3721 | ? |
| 8 | 5.631 | VV | 0.1155 | 31.65069 | 0.4767 | ? |

Sample Name: GR-16-165 spl 2

| Peak # | RetTime [min] | Type | Width [min] | Area [mAU*s] | Area % | Name |
|--------|---------------|------|-------------|--------------|--------|------|
| 9 | 5.797 | VB | 0.1191 | 12.25093 | 0.1845 | ? |

Totals : 6639.96441

=====
*** End of Report ***